COPYRIGHT© 2018 吉林紫鑫药业股份有限公司
Announcement on Resolutions of the Fifth Meeting of the Fifth Board of Supervisors of Jilin Zixin Pharmaceutical Co., Ltd.
Stock code: 002118 Securities abbreviation: Zixin Pharmaceutical Announcement No.: 2014-002
Jilin Zixin Pharmaceutical Co., Ltd.
Announcement on Resolutions of the Fifth Session of the Fifth Board of Supervisors
The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate and complete, and there are no false records, misleading statements or major omissions.
The fifth meeting of the fifth session of the Supervisory Committee of Jilin Zixin Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) was held on January 8, 2014 by means of communication and on-site voting. The meeting notice was written or written on December 27, 2013. E-mails, etc. are issued in accordance with the provisions of the Company Law and the Articles of Association. The meeting should attend 3 supervisors and 3 actual supervisors. The supervisor Zhang Hongfa voted by means of communication. Hosted by Supervisor Tian Feng.
After careful consideration by the attending supervisors, the following proposals were passed:
The “Proposal on Permanently Supplementing Working Capital for Individually Raised Funds” was reviewed and approved.
Review results: 3 votes in favor, 0 votes against, and 0 abstentions.
The Board of Supervisors' opinions: The company's single raised funds will permanently supplement the working capital, which is in line with the "Guidelines for the Standardized Operation of the SME Board Listed Companies of Shenzhen Stock Exchange", "SME Information Disclosure Business Memorandum No. 29: Use of Raised Funds" and the Company" Relevant regulations such as the fundraising management system, there is no illegal use of raised funds and damage to the interests of investors, which is conducive to improving the efficiency of the use of funds raised by the company, in line with the interests of all shareholders of the company, and the ginseng product serialization project (Yanji factory area) The permanent replenishment of liquidity by funds does not have any impact on other fundraising projects. It is agreed that the company will balance the surplus of raised funds from the ginseng product serialization project (Yanji Plant) with a balance of approximately RMB 25,374,400 (including interest income). The proposal needs to be submitted to the company's first extraordinary shareholders meeting in 2014 for consideration and approval.
Jilin Zixin Pharmaceutical Co., Ltd. Board of Directors
January 9, 2014